An adaptive dose-finding design incorporating both toxicity and efficacy

Wei Zhang1, Daniel J Sargent, Sumithra Mandrekar

  • 1Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA.

Statistics in Medicine
|October 13, 2005
PubMed

Insights

This study introduces TriCRM, a novel approach for phase I clinical trials. TriCRM optimizes drug dose selection by integrating both toxicity and efficacy data, improving novel therapy development.

Area of Science:

  • Clinical Pharmacology
  • Biostatistics
  • Drug Development

Background:

  • Novel therapies require innovative drug development strategies.
  • Determining optimal doses for targeted agents with low toxicity is challenging.
  • Phase I trials need efficient designs to advance promising treatments.

Purpose of the Study:

  • To present a novel dose-finding approach for phase I trials.
  • To integrate both toxicity and efficacy data for optimal dose estimation.
  • To introduce the TriCRM design for biologically optimal dose selection.

Main Methods:

  • Utilizes a flexible continuation-ratio model.
  • Employs straightforward optimal dose selection criteria.
  • Incorporates a continual reassessment method (CRM) for adaptive dose adjustments.

Main Results:

  • The TriCRM design effectively estimates the biologically optimal dose.
  • Considers various dose-outcome relationships (increasing, decreasing, unimodal).
  • Simulation studies confirm favorable operating characteristics of TriCRM.

Conclusions:

  • TriCRM offers an improved method for dose selection in early-phase drug development.
  • This approach enhances the efficiency of identifying optimal doses for novel agents.
  • The integration of toxicity and efficacy data leads to more robust dose determination.

Related Concept Videos

Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...